Literature DB >> 32048065

Prognostic Biomarkers for Melanoma Immunotherapy.

Christopher G Twitty1, Laura A Huppert2, Adil I Daud3.   

Abstract

PURPOSE OF REVIEW: Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy. RECENT
FINDINGS: Current immunotherapies disable immune checkpoints on T cells and other immune cells and allow immune rejection of tumor. This process depends crucially on a preexisting response to the development of the melanoma. Here we describe the complexity of the anti-tumor immune response and the links to the development of markers that are currently used or under investigation in the clinic. We describe immune response biomarkers along with new developments that could translate into advances.

Entities:  

Keywords:  Circulating tumor DNA; Exhausted T cells (Tex); Immune checkpoint inhibitors; Memory T cells (Tmem); Programmed death ligand-1 (PD-L1); Programmed death-1 (PD-1); Tumor microenvironment (TME); Tumor mutation burden

Mesh:

Substances:

Year:  2020        PMID: 32048065     DOI: 10.1007/s11912-020-0886-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  94 in total

1.  NR4A transcription factors limit CAR T cell function in solid tumours.

Authors:  Joyce Chen; Isaac F López-Moyado; Hyungseok Seo; Chan-Wang J Lio; Laura J Hempleman; Takashi Sekiya; Akihiko Yoshimura; James P Scott-Browne; Anjana Rao
Journal:  Nature       Date:  2019-02-27       Impact factor: 49.962

2.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

3.  Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Authors:  Rajarsi Mandal; Robert M Samstein; Ken-Wing Lee; Jonathan J Havel; Hao Wang; Chirag Krishna; Erich Y Sabio; Vladimir Makarov; Fengshen Kuo; Pedro Blecua; Apoorva T Ramaswamy; Jennifer N Durham; Bjarne Bartlett; Xiaoxiao Ma; Raghvendra Srivastava; Sumit Middha; Ahmet Zehir; Jaclyn F Hechtman; Luc Gt Morris; Nils Weinhold; Nadeem Riaz; Dung T Le; Luis A Diaz; Timothy A Chan
Journal:  Science       Date:  2019-05-03       Impact factor: 47.728

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 5.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

6.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Authors:  Frank Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Charles Lance Cowey; Christopher D Lao; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier Francesco Ferrucci; Michael Smylie; Andrew Hill; David Hogg; Ivan Marquez-Rodas; Joel Jiang; Jasmine Rizzo; James Larkin; Jedd D Wolchok
Journal:  Lancet Oncol       Date:  2018-10-22       Impact factor: 41.316

7.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.

Authors:  Gerald S Falchook; Rom Leidner; Elizabeth Stankevich; Brian Piening; Carlo Bifulco; Israel Lowy; Matthew G Fury
Journal:  J Immunother Cancer       Date:  2016-11-15       Impact factor: 13.751

9.  TOX is a critical regulator of tumour-specific T cell differentiation.

Authors:  Andrew C Scott; Friederike Dündar; Paul Zumbo; Smita S Chandran; Christopher A Klebanoff; Mojdeh Shakiba; Prerak Trivedi; Laura Menocal; Heather Appleby; Steven Camara; Dmitriy Zamarin; Tyler Walther; Alexandra Snyder; Matthew R Femia; Elizabeth A Comen; Hannah Y Wen; Matthew D Hellmann; Niroshana Anandasabapathy; Yong Liu; Nasser K Altorki; Peter Lauer; Olivier Levy; Michael S Glickman; Jonathan Kaye; Doron Betel; Mary Philip; Andrea Schietinger
Journal:  Nature       Date:  2019-06-17       Impact factor: 49.962

10.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

Authors:  Daniela S Thommen; Viktor H Koelzer; Petra Herzig; Andreas Roller; Marcel Trefny; Sarah Dimeloe; Anna Kiialainen; Jonathan Hanhart; Catherine Schill; Christoph Hess; Spasenija Savic Prince; Mark Wiese; Didier Lardinois; Ping-Chih Ho; Christian Klein; Vaios Karanikas; Kirsten D Mertz; Ton N Schumacher; Alfred Zippelius
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

View more
  5 in total

Review 1.  Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.

Authors:  Massimo Ralli; Andrea Botticelli; Irene Claudia Visconti; Diletta Angeletti; Marco Fiore; Paolo Marchetti; Alessandro Lambiase; Marco de Vincentiis; Antonio Greco
Journal:  J Immunol Res       Date:  2020-06-28       Impact factor: 4.818

2.  Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment.

Authors:  Kristen E Pauken; Osmaan Shahid; Kaitlyn A Lagattuta; Kelly M Mahuron; Jacob M Luber; Margaret M Lowe; Linglin Huang; Conor Delaney; Jaclyn M Long; Megan E Fung; Kathleen Newcomer; Katy K Tsai; Melissa Chow; Samantha Guinn; Juhi R Kuchroo; Kelly P Burke; Jason M Schenkel; Michael D Rosenblum; Adil I Daud; Arlene H Sharpe; Meromit Singer
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

3.  Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma.

Authors:  Qinghua Wang; Juncheng Lyu; Wenjing Zhang; Fuyan Shi; Yanfeng Ren; Qian Mao; Yujie Liu; Yuting Li; Suzhen Wang
Journal:  Aging (Albany NY)       Date:  2021-11-08       Impact factor: 5.682

4.  Construction of a Ferroptosis-Related Gene Signature for Predicting Survival and Immune Microenvironment in Melanoma Patients.

Authors:  Ni Zeng; Liwen Ma; Yuxin Cheng; Qingyue Xia; Yueyue Li; Yihe Chen; Zhiyu Lu; Qian Lu; Feng Jiang; Dan Luo
Journal:  Int J Gen Med       Date:  2021-10-05

5.  Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.

Authors:  Shang-Jui Wang; Karishma Khullar; Sinae Kim; Nikhil Yegya-Raman; Jyoti Malhotra; Roman Groisberg; Samuel H Crayton; Ann W Silk; John L Nosher; Michael A Gentile; Janice M Mehnert; Salma K Jabbour
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.